These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7738956)

  • 1. von Willebrand factor in juvenile dermatomyositis.
    Bloom BJ; Tucker LB; Miller LC; Schaller JG
    J Rheumatol; 1995 Feb; 22(2):320-5. PubMed ID: 7738956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes.
    Guzmán J; Petty RE; Malleson PN
    J Rheumatol; 1994 Apr; 21(4):739-43. PubMed ID: 8035403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble adhesion molecules in pediatric rheumatic diseases.
    Bloom BJ; Miller LC; Blier PR
    J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy.
    Kimball AB; Summers RM; Turner M; Dugan EM; Hicks J; Miller FW; Rider LG
    Arthritis Rheum; 2000 Aug; 43(8):1866-73. PubMed ID: 10943878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
    Shihong I; Morris D; Konkle BA
    Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis.
    Maillard SM; Jones R; Owens CM; Pilkington C; Woo PM; Wedderburn LR; Murray KJ
    Arthritis Rheum; 2005 Aug; 53(4):558-64. PubMed ID: 16082634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2.
    Klemm T; Mehnert AK; Siegemund A; Wiesner TD; Gelbrich G; Blüher M; Paschke R
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):568-72. PubMed ID: 16320153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of von Willebrand factor in patients with adult dermatomyositis.
    Komiya T; Negoro N; Kondo K; Miura K; Hirota Y; Yoshikawa J
    Clin Rheumatol; 2005 Aug; 24(4):352-7. PubMed ID: 15565394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatomyositis in six patients without initial muscle involvement.
    Krain L
    Arch Dermatol; 1975 Feb; 111(2):241-5. PubMed ID: 1078762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.
    Catto AJ; Carter AM; Barrett JH; Bamford J; Rice PJ; Grant PJ
    Thromb Haemost; 1997 Jun; 77(6):1104-8. PubMed ID: 9241740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis.
    Escalante A; Miller L; Beardmore TD
    J Rheumatol; 1993 Aug; 20(8):1340-4. PubMed ID: 8230016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.
    Apaz MT; Saad-Magalhães C; Pistorio A; Ravelli A; de Oliveira Sato J; Marcantoni MB; Meiorin S; Filocamo G; Pilkington C; Maillard S; Al-Mayouf S; Prahalad S; Fasth A; Joos R; Schikler K; Mozolova D; Landgraf JM; Martini A; Ruperto N;
    Arthritis Rheum; 2009 Apr; 61(4):509-17. PubMed ID: 19333974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy.
    Naim MY; Reed AM
    J Rheumatol; 2006 Jul; 33(7):1392-4. PubMed ID: 16821273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association among somatic HPRT mutant frequency, peripheral blood T-lymphocyte clonality, and serologic parameters of disease activity in children with juvenile onset dermatomyositis.
    Abramson LS; Albertini RJ; Pachman LM; Finette BA
    Clin Immunol; 1999 Apr; 91(1):61-7. PubMed ID: 10219255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of illness is an important variable for untreated children with juvenile dermatomyositis.
    Pachman LM; Abbott K; Sinacore JM; Amoruso L; Dyer A; Lipton R; Ilowite N; Hom C; Cawkwell G; White A; Rivas-Chacon R; Kimura Y; Ray L; Ramsey-Goldman R
    J Pediatr; 2006 Feb; 148(2):247-53. PubMed ID: 16492437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscular strength as an index of response to therapy in childhood dermatomyositis.
    Resnick JS; Mammel M; Mundale MO; Kottke FJ
    Arch Phys Med Rehabil; 1981 Jan; 62(1):12-9. PubMed ID: 7458626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.